Form 4: Spyre Therapeutics Director Jeffrey Albers Granted 25,000 Stock Options

Spyre Therapeutics, Inc. Director Jeffrey W. Albers was granted 25,000 stock options with an exercise price of $15.55, vesting over 12 months.

Summary

• Jeffrey W. Albers, a Director of Spyre Therapeutics, Inc. (SYRE), was granted 25,000 stock options.
• The transaction date for this grant was May 29, 2025.
• Each stock option has an exercise price of $15.55.
• The options will vest and become exercisable in 12 equal monthly installments following May 29, 2025.
• Full vesting is contingent upon Mr. Albers' continuous service with Spyre Therapeutics at each vesting date.
• The expiration date for these stock options is May 29, 2035.
• Following this transaction, Mr. Albers directly beneficially owns 25,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: Slightly positive as it indicates continued alignment of a director's interests with the company's performance through equity compensation, which is a standard and generally well-regarded practice.

Positives

• The grant of stock options aligns the director's financial interests with the long-term performance and success of Spyre Therapeutics, incentivizing value creation for shareholders.
• This is a standard form of equity compensation, indicating continued commitment and engagement of the director with the company.

Risks

• The value of the stock options is dependent on the future market price of Spyre Therapeutics' common stock exceeding the exercise price of $15.55.
• The options are subject to forfeiture if the reporting person's continuous service with the Issuer terminates before full vesting.

Future Outlook

The vesting schedule of the stock options over 12 months implies a continued commitment of the director to the company's long-term performance and strategic objectives.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industry to incentivize long-term commitment and align interests with shareholders, particularly for companies like Spyre Therapeutics [SYRE] which are often in growth or development phases.

Comparison to Industry Standards

• Granting stock options to directors is a standard compensation practice across publicly traded companies, especially in the biotech sector, to align executive and director incentives with shareholder value creation.
• While specific grant sizes vary based on company size, stage, and individual roles, a grant of 25,000 options for a director is within typical ranges for a company of Spyre Therapeutics' profile, comparable to practices seen at similar-stage biopharmaceutical companies.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic decisions.
• Employees: No direct impact on employees mentioned in this filing.
• Customers: No direct impact on customers mentioned in this filing.
• Suppliers: No direct impact on suppliers mentioned in this filing.
• Creditors: No direct impact on creditors mentioned in this filing.

Next Steps

• The granted stock options will vest in 12 equal monthly installments following May 29, 2025, subject to the director's continuous service.

Key Dates

Keywords

Spyre Therapeutics, SYRE, Form 4, Insider Transaction, Stock Options, Director Compensation, Equity Grant, Beneficial Ownership, SEC Filing